Corbus 15min chart shows KDJ Death Cross and Bearish Marubozu signal.
ByAinvest
Friday, Jul 18, 2025 12:18 pm ET1min read
CRBP--
On July 18, 2025, at 12:15, the 15-minute chart of Corbus exhibited a bearish trend, as indicated by a KDJ Death Cross and a Bearish Marubozu pattern [2]. These technical indicators suggest that the stock price momentum is shifting towards the downside, with potential for further decreases in value. Sellers currently dominate the market, indicating that this bearish momentum may continue.
In comparison, Vanda Pharmaceuticals Inc. (VNDA) rose 1.05% to $4.81, Fortress Biotech Inc. (FBIO) gained 1.55% to $1.97, and Viking Therapeutics Inc. (VKTX) increased 3.03% to $31.63. Corbus's performance on Wednesday was notable, as it outperformed these competitors despite the bearish technical indicators.
Trading volume for Corbus was 78,471, remaining 82,713 below its 50-day average volume of 161,184. This suggests that while interest in the stock remains, it is not at its peak.
References:
[1] https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-060d1719-700562c9a7a0
[2] (Provided Writing Topic)
FBIO--
VKTX--
VNDA--
The 15-minute chart of Corbus has exhibited a bearish trend, as evidenced by a KDJ Death Cross and a Bearish Marubozu pattern on July 18, 2025, at 12:15. This suggests that the momentum of the stock price is shifting towards the downside, with a potential for further decreases in value. Sellers currently dominate the market, and it is likely that this bearish momentum will continue.
Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock price rally 5.71% to $8.52 on Wednesday, outperforming several competitors during an overall positive trading session for the stock market [1]. The NASDAQ Composite Index (COMP) rose 0.25% to 20,730.49, while the Dow Jones Industrial Average (DJIA) climbed 0.53% to 44,254.78. Despite the market's gains, Corbus closed 86.24% below its 52-week high of $61.90, reached on July 31st.On July 18, 2025, at 12:15, the 15-minute chart of Corbus exhibited a bearish trend, as indicated by a KDJ Death Cross and a Bearish Marubozu pattern [2]. These technical indicators suggest that the stock price momentum is shifting towards the downside, with potential for further decreases in value. Sellers currently dominate the market, indicating that this bearish momentum may continue.
In comparison, Vanda Pharmaceuticals Inc. (VNDA) rose 1.05% to $4.81, Fortress Biotech Inc. (FBIO) gained 1.55% to $1.97, and Viking Therapeutics Inc. (VKTX) increased 3.03% to $31.63. Corbus's performance on Wednesday was notable, as it outperformed these competitors despite the bearish technical indicators.
Trading volume for Corbus was 78,471, remaining 82,713 below its 50-day average volume of 161,184. This suggests that while interest in the stock remains, it is not at its peak.
References:
[1] https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-060d1719-700562c9a7a0
[2] (Provided Writing Topic)
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet